Eli Lilly said on Monday it would buy cancer therapy developer Scorpion Therapeutics for up to $2.5 billion in cash. Lilly will acquire Scorpion's experimental oral therapy, STX-478, which is ...
The Indianapolis-based drugmaker will acquire Scorpion’s STX-478, a once-daily oral treatment in early trials for breast cancer and other advanced solid tumors.
Eli Lilly said on Monday it plans to buy Scorpion Therapeutics' experimental cancer therapy for up to $2.5 billion in cash to expand its pipeline of cancer treatments. The company will acquire ...